Scientists uncover new mechanism that enables development of cancer
(UNC Lineberger Comprehensive Cancer Center) Researchers at the University of North Carolina at Chapel Hill have uncovered a mechanism that activates specific genes, leading to the development of cancers. They showed that a mutation that fuses two unrelated genes can promote a process similar to that observed when oil and water are mixed but do not blend together. The process, called liquid-liquid phase separation, can promote cancers such as acute leukemias. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2021 Category: Cancer & Oncology Source Type: news

Incidence Rates of Pediatric Cancers Vary by Race, Ethnicity
Variation seen by single year of age, including lower incidence of acute lymphoblastic leukemia in Blacks, especially at 1 to 7, 16 to 20 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 21, 2021 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Journal, Source Type: news

Reduced-Intensity Transplant Benefits Older Patients With AML Reduced-Intensity Transplant Benefits Older Patients With AML
Results from two large trials show that for older patients with acute myeloid leukemia (AML), survival is improved if they receive reduced-intensity conditioning before transplant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

MD Anderson research highlights for June 16, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) inf...
Source: EurekAlert! - Cancer - June 16, 2021 Category: Cancer & Oncology Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of re...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia
Hematology / Oncology Approvals (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the latest data from three pivotal phase III studies of Venclexta ®/Venclyxto® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta/Venclyxto in chronic lymphocytic leukaemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors. Furthermore, the latest research shows the potential of minimal residual disease (MRD) as a key meas...
Source: Roche Media News - June 11, 2021 Category: Pharmaceuticals Source Type: news

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the latest data from three pivotal phase III studies of Venclexta ®/Venclyxto® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta/Venclyxto in chronic lymphocytic leukaemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors. Furthermore, the latest research shows the potential of minimal residual disease (MRD) as a key meas...
Source: Roche Investor Update - June 11, 2021 Category: Pharmaceuticals Source Type: news

1980 to 2017 Saw Improved Survival for Acute Myeloid Leukemia
THURSDAY, June 10, 2021 -- From 1980 to 2017, there was improvement in survival for acute myeloid leukemia (AML) in all age groups, except for those aged≥70 years, according to a study published in the June 15 issue of Cancer. Koji Sasaki,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 10, 2021 Category: Pharmaceuticals Source Type: news

Venetoclax Shows Activity Against T-ALL in Children Venetoclax Shows Activity Against T-ALL in Children
Data from a small retrospective study suggest that venetoclax-based regimens may have activity against relapsed or refractory T-lineage acute lymphoblastic leukemia in children and young adults.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

When cancer cells " put all their eggs in one basket "
(Cold Spring Harbor Laboratory) Normal cells usually have multiple solutions for fixing problems that may arise. But cancer cells may " put all their eggs in one basket, " getting rid of all backup plans and depending on just one solution. CSHL Professor Christopher Vakoc's lab discovered that a particular type of blood cancer, acute myeloid leukemia, came to depend on a single DNA repair method. They developed a drug that shut down the remaining pathway in lab-grown cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 27, 2021 Category: Cancer & Oncology Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Media News)
Source: Roche Media News - May 25, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - May 25, 2021 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: World Pharma News)
Source: World Pharma News - May 25, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news